WO2011161438A3 - Biomarkers for autism spectrum conditions, in particular asperger syndrome - Google Patents

Biomarkers for autism spectrum conditions, in particular asperger syndrome Download PDF

Info

Publication number
WO2011161438A3
WO2011161438A3 PCT/GB2011/051145 GB2011051145W WO2011161438A3 WO 2011161438 A3 WO2011161438 A3 WO 2011161438A3 GB 2011051145 W GB2011051145 W GB 2011051145W WO 2011161438 A3 WO2011161438 A3 WO 2011161438A3
Authority
WO
WIPO (PCT)
Prior art keywords
biomarkers
autism spectrum
asperger syndrome
spectrum conditions
conditions
Prior art date
Application number
PCT/GB2011/051145
Other languages
French (fr)
Other versions
WO2011161438A2 (en
Inventor
Sabine Bahn
Emanuel Schwarz
Original Assignee
Cambridge Enterprise Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Enterprise Limited filed Critical Cambridge Enterprise Limited
Publication of WO2011161438A2 publication Critical patent/WO2011161438A2/en
Publication of WO2011161438A3 publication Critical patent/WO2011161438A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5434—IL-12
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Abstract

The invention relates to a method of diagnosing or monitoring autism spectrum conditions, in particular Asperger syndrome.
PCT/GB2011/051145 2010-06-21 2011-06-20 Biomarkers WO2011161438A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1010316.6 2010-06-21
GBGB1010316.6A GB201010316D0 (en) 2010-06-21 2010-06-21 Biomarkers

Publications (2)

Publication Number Publication Date
WO2011161438A2 WO2011161438A2 (en) 2011-12-29
WO2011161438A3 true WO2011161438A3 (en) 2013-01-03

Family

ID=42582675

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2011/051145 WO2011161438A2 (en) 2010-06-21 2011-06-20 Biomarkers

Country Status (2)

Country Link
GB (1) GB201010316D0 (en)
WO (1) WO2011161438A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150309053A1 (en) * 2012-10-23 2015-10-29 Riken Test method and test kit for psychiatric ailments
CN109142744A (en) * 2018-07-26 2019-01-04 珠海中科先进技术研究院有限公司 A kind of autism spectrum disorder diagnostic kit
EP4348265A2 (en) * 2021-05-25 2024-04-10 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Diagnosis of autism spectrum disorder by multiomics platform

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009077763A1 (en) * 2007-12-19 2009-06-25 Psynova Neurotech Limited Methods and biomarkers for diagnosing and monitoring psychotic disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009077763A1 (en) * 2007-12-19 2009-06-25 Psynova Neurotech Limited Methods and biomarkers for diagnosing and monitoring psychotic disorders

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ASHWOOD P ET AL: "Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome", BRAIN, BEHAVIOR AND IMMUNITY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 25, no. 1, 1 January 2011 (2011-01-01), pages 40 - 45, XP027514166, ISSN: 0889-1591, [retrieved on 20100810], DOI: 10.1016/J.BBI.2010.08.003 *
E SCHWARZ ET AL: "Sex-specific serum biomarker patterns in adults with Asperger's syndrome", MOLECULAR PSYCHIATRY, 1 September 2010 (2010-09-01), XP055010271, ISSN: 1359-4184, DOI: 10.1038/mp.2010.102 *
JYONOUCHI H ET AL: "Evaluation of an association between gastrointestinal symptoms and cytokine production against common dietary proteins in children with autism spectrum disorders", JOURNAL OF PEDIATRICS, MOSBY-YEAR BOOK, ST. LOUIS, MO, US, vol. 146, no. 5, 1 May 2005 (2005-05-01), pages 605 - 610, XP027277967, ISSN: 0022-3476, [retrieved on 20050430] *
KATSUAKI SUZUKI ET AL: "Plasma Cytokine Profiles in Subjects with High-Functioning Autism Spectrum Disorders", PLOS ONE, vol. 6, no. 5, 1 January 2011 (2011-01-01), pages E20470 - E20470, XP055010291, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0020470 *
SINGH V K: "PLASMA INCREASE OF INTERLEUKIN-12 AND INTERFERON-GAMMA PATHOLOGICAL SIGNIFICANCE IN AUTISM", JOURNAL OF NEUROIMMUNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, XX, vol. 66, 1 January 1996 (1996-01-01), pages 143 - 145, XP002977203, ISSN: 0165-5728, DOI: 10.1016/0165-5728(96)00014-8 *
VIJENDRA K. SINGH ET AL: "Phenotypic expression of autoimmune autistic disorder (AAD): a major subset of autism.", ANNALS OF CLINICAL PSYCHIATRY, vol. 21, no. 3, 1 September 2009 (2009-09-01), pages 148 - 161, XP055010290, DOI: 10.1159/000065007 *

Also Published As

Publication number Publication date
GB201010316D0 (en) 2010-08-04
WO2011161438A2 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
WO2011031786A3 (en) Compositions and methods for diagnosing autism spectrum disorders
WO2012012725A3 (en) Methods of detecting diseases or conditions using phagocytic cells
WO2012009567A3 (en) Biomarkers for diagnosis of stroke and its causes
WO2013014286A3 (en) Means and methods for diagnosing and monitoring heart failure in a subject
WO2012061603A3 (en) Compositions comprising and methods for forming functionalized carbon-based nanostructures
PT2737346T (en) Luminous glazing unit for vehicle, manufacture thereof
WO2012006476A3 (en) Methods and compositions for quantifying exosomes
EP2610071A4 (en) Tire, and manufacturing method for same
PL2711350T3 (en) Method for manufacturing 1,3-butadiene
PL2649242T3 (en) Method for building structures, particularly passages under operating railways or the like.
WO2010110599A3 (en) Novel αlpha-neoagarobiose hydrolase, and method for obtaining a monosaccharide using same
EP2443457A4 (en) Methods, systems and kits for detecting protein-nucleic acid interactions
WO2010075360A3 (en) Methods for detection of sepsis
WO2010015657A3 (en) Alkoxypyrazoles and the process for their preparation
EP2586761A4 (en) Method for manufacturing 2,3,3,3-tetrafluoropropene
WO2014063670A3 (en) Method for producing a nanoporous layer on a substrate
BR112012003958A2 (en) method for producing an 1-amino acid.
WO2010112452A9 (en) Oligocondensed perylene bisimides
WO2012154908A3 (en) Hairy cell leukemia biomarkers and methods of using same
WO2012012709A3 (en) Methods of detecting cardiovascular diseases or conditions
WO2013072060A8 (en) Method for the diagnosis of niemann-pick disease
EP2474516A4 (en) Method for manufacturing 2,3,3,3-tetrafluoropropene
IT1396782B1 (en) COMPOUND FOR TIRES WITH IMPROVED ROLLING RESISTANCE.
WO2012064743A3 (en) Methods for improving heart function
WO2012106680A8 (en) Methods and compositions for chemical drying and producing struvite

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11728922

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11728922

Country of ref document: EP

Kind code of ref document: A2